Key result
COVID-19 pandemic linked to a ~47% increase in myocarditis mortality, reversing a two-decade decline.
Why the study?
Trends in myocarditis-related mortality in the United States, including demographic and regional disparities and the impact of the COVID-19 pandemic, were unknown.
Observational (n=33,016)
Absolute Event Rate: 5.85% vs 3.99%
Myocarditis mortality in the US steadily declined from 1999 to 2019 but experienced a sharp, significant reversal during the COVID-19 pandemic, largely driven by COVID-19 infections.
Supports heightened myocarditis surveillance during viral outbreaks; leaves open causal mechanisms and prevention targets.
Background: Myocarditis is associated with increased mortality due to complications such as cardiogenic shock and arrhythmia. Trends of myocarditis-related mortality in the United States, along with demographic and regional disparities and changes during the COVID-19 pandemic, are unknown. Methods: We used the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database to extract data for myocarditis deaths from 1999 to 2023. The Joinpoint Regression Program was used to analyze long-term trends in mortality, and R Studio (version 4.4.1) was used to calculate expected and excess mortality for 2020 to 2023. Results: There were 33,016 myocarditis-related deaths from 1999 to 2023. The age-adjusted mortality rate (AAMR) of myocarditis deaths decreased by 46.08% from 7.40 (95% CI: 7.04–7.76) in 1999 to 3.99 (95% CI: 3.74–4.23) in 2019, with an APC of −2.59 (95% CI: −2.97 to −2.24). From 2019 to 2021, the AAMR increased by 46.62% to 5.85 (95% CI: 5.56–6.14) by 2021 (2019–2021 APC 22.3%*), reversing the gains of the previous two decades. By 2023, the AAMR recovered to 4.33 (95% CI: 4.09 to 4.58), though mortality was still higher than expected from pre-pandemic trends. From 2020 to 2023, there were 40.12% more deaths than expected, with 54.94% higher mortality in 2021. Briefly, 70.33% of excess myocarditis-related deaths also had COVID-19, with a peak of 76.15% of excess myocarditis deaths in 2021 being reported as involving COVID-19 infection. Significant disparities in mortality trends persisted, with males, NH Black or African Americans, and the elderly having higher mortality rates. Conclusions: Myocarditis mortality decreased in the United States from 1999 to 2019 but significantly increased during the COVID-19 pandemic years 2020 and 2021. At the height of the pandemic, COVID-19 infection contributed to almost three-quarters of excess myocarditis mortality. Significant disparities in myocarditis mortality persisted from 1999 to 2023.
No takes yet. Share an insight, caveat, or question.
Jabbar et al. (2025) conducted an observational in Myocarditis (n=33,016). COVID-19 pandemic vs. Pre-pandemic period (1999-2019) was evaluated on Age-adjusted mortality rate (AAMR) of myocarditis deaths. The COVID-19 pandemic reversed a two-decade decline in myocarditis mortality, with the age-adjusted mortality rate increasing by 46.62% from 3.99 in 2019 to 5.85 in 2021.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: